Global In-Vitro Diagnostics Market to Reach Worth USD 81.35 Bn by 2022: Credence Research

General News

Summary

Additionally, the software and services segment is anticipated to progress at a faster growth rate during the forecast period attributed by the growing need for widest automation and centralization of IVD processes and techniques at a precision at par.Its prospects in novel drug discovery and personalized medicine also plays a critical role in facilitating lucrative market growth during the forecast period.For More Information, Visit: Credence Research Media Contact Company Name: Credence Research Contact Person: Chris Smith, Designation: Global Sales Manager Phone: 1-800-361-8290 Address: 105 N 1st ST #429, San Jose, CA 95103 E-mail: sales@credenceresearch.com San Jose, CA, May 28, 2016 --( PR.com )-- According to the latest report published by Credence Research, Inc. “Global In-vitro Diagnostics Market - Growth, Opportunities, Competitive Analysis, and Forecast, 2016 - 2022,” the in-vitro diagnostics market was valued at USD 60,468.7 Mn in 2015, and is expected to reach USD 81,345.1 Mn by 2022, expanding at a CAGR of 4.2% from 2016 to 2022.Browse the full report Global In-vitro Diagnostics Market - Growth, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 report at http://www.credenceresearch.com/report/in-vitro-diagnostics-ivd-marketMarket InsightsThe need for in-vitro diagnostics is on a consistent rise due to growing incidence of chronic diseases, infections and high risk ageing population.Its prospects in novel drug discovery and personalized medicine also plays a critical role in facilitating lucrative market growth during the forecast period.For each engagement, we collect a group with the most suitable experience and ability.No matter the challenge, we concentrate on delivering functional and persevering results, and preparing our customers to develop and lead.

Classifications

industries
No industries detected
applications
No applications detected

AskAI Classifications

Labels
No AI classifications detected

Linked Companies